Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis

HIGHLIGHTS

• who: Josu00e9 A. Villegas from the (Strasbourg, France), and Cochin University Hospital group (Paris, France)Five MG patients aged , to , years old with anti-AChR antibodies but without thymoma were included. The patients were stabilized before the thymectomy. They have different severity scores and were on ocular stage, however they have gone through generalized disease stage. Study approval for mouse models have published the article: Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis, in the Journal: (JOURNAL)
• what: The authors aimed to study a potential new therapeutic approach that targets IL-23p19 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.